Bio-Gene Technology Limited (ASX:BGT)

Bio-Gene Technology Income Statement

Financials in millions AUD. Fiscal year is July - June.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Revenue	-	0.02	0.15	0.45	0.06
Revenue Growth (YoY)	-	-87.72%	-66.52%	611.91%	-49.01%
Cost of Revenue	0.25	0.32	0.27	0.22	0.12
Gross Profit	-0.25	-0.3	-0.12	0.22	-0.06
Selling, General & Admin	1.44	1.69	1.48	1.23	0.87
Research & Development	1.38	1.07	1.98	1.9	1.68
Other Operating Expenses	-0.48	-0.6	-0.45	0.02	-0.22
Operating Expenses	2.38	2.19	3.06	3.19	2.38
Operating Income	-2.62	-2.5	-3.18	-2.97	-2.43
Interest Expense	-	-	-	-	-0
Interest & Investment Income	0.04	0.09	0.09	0.05	0.04
Other Non Operating Income (Expenses)	0	-0	-	-	-
EBT Excluding Unusual Items	-2.58	-2.41	-3.1	-2.91	-2.4
Pretax Income	-2.58	-2.41	-3.1	-2.91	-2.4
Net Income	-2.58	-2.41	-3.1	-2.91	-2.4
Net Income to Common	-2.58	-2.41	-3.1	-2.91	-2.4
Shares Outstanding (Basic)	211	186	168	153	137
Shares Outstanding (Diluted)	211	186	168	153	137
Shares Change (YoY)	13.68%	10.76%	9.41%	11.73%	14.96%
EPS (Basic)	-0.01	-0.01	-0.02	-0.02	-0.02
EPS (Diluted)	-0.01	-0.01	-0.02	-0.02	-0.02
Free Cash Flow	-2.54	-2.76	-3.28	-2	-1.83
Free Cash Flow Per Share	-0.01	-0.01	-0.02	-0.01	-0.01
Gross Margin	-	-	-79.57%	49.83%	-90.03%
Operating Margin	-	-13625.67%	-2132.08%	-665.67%	-3887.62%
Profit Margin	-	-13150.54%	-2074.48%	-653.81%	-3827.29%
Free Cash Flow Margin	-	-15065.19%	-2195.48%	-448.66%	-2920.54%
EBITDA	-2.58	-2.46	-3.14	-2.92	-2.39
D&A For EBITDA	0.04	0.04	0.05	0.04	0.04
EBIT	-2.62	-2.5	-3.18	-2.97	-2.43
Revenue as Reported	0.52	0.71	0.68	0.94	0.64

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.